LOTUSEYE · NSE
Lotus Eye Hospital and Institute Limited
₹115.24
+0.23% (+₹0.27)
Prev. close
₹114.97
Volume
5,314
Delivery %
78.4%
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Lotus Eye Hospital and Institute Limited
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch-free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive errors, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and corneal infections, as well as various eye-related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Ramanujam Reghunathan
Headquarters
Coimbatore
Employees
402
Website
lotuseye.orgExchange
View on NSE ↗Key stats
Market cap
₹239.66 Cr
P/E ratio (TTM)
1440.5
EPS (TTM)
₹0.08
Beta (1Y · daily vs NIFTY 50)
0.93
Beta (5Y · monthly vs NIFTY 50)
1.27
Shares float
46.47 L
EPS · quarter ended Jun 2026
₹0.30
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 2.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹32.37 Cr | ₹38.91 Cr | ₹47.04 Cr | ₹48.21 Cr | ₹49.56 Cr | ₹53.71 Cr | |
| EBITDA | ₹4.39 Cr | ₹6.72 Cr | ₹8.73 Cr | ₹7.84 Cr | ₹4.74 Cr | ₹4.56 Cr |
| ₹1.57 Cr | ₹2.98 Cr | ₹4.08 Cr | ₹2.91 Cr | ₹73.93 L | ₹8.04 L | |
| Diluted EPS | ₹0.51 | ₹0 | ₹1.96 | ₹1.4 | ₹0.36 | ₹0.04 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹59.22 Cr | ₹61.60 Cr | ₹63.18 Cr | ₹66.63 Cr | ₹69.57 Cr | ₹82.60 Cr | |
| — | — | ₹67.04 L | ₹1.11 Cr | ₹3.43 Cr | ₹15.83 Cr | |
| Stockholders' equity | ₹52.70 Cr | ₹54.61 Cr | ₹57.58 Cr | ₹59.41 Cr | ₹60.00 Cr | ₹60.14 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2.73 Cr | ₹4.41 Cr | ₹4.39 Cr | ₹5.68 Cr | ₹2.70 Cr | ₹3.02 Cr | |
| Investing cash flow | ₹48.55 L | ₹-3.92 Cr | ₹-2.19 Cr | ₹-4.63 Cr | ₹-3.99 Cr | ₹-12.37 Cr |
| ₹-32.00 L | ₹-1.58 Cr | ₹-1.71 Cr | ₹-3.40 Cr | ₹-1.60 Cr | ₹9.03 Cr | |
| Capital expenditure | ₹-48.00 L | ₹-4.68 Cr | ₹-3.10 Cr | ₹-5.57 Cr | ₹-4.83 Cr | ₹-12.95 Cr |
| End cash position | ₹9.89 Cr | ₹8.79 Cr | ₹9.28 Cr | ₹2.65 Cr | ₹2.01 Cr | ₹1.81 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 22(4Q) | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.74% | 57.88% | 58.14% | 58.17% | 58.43% | 57.58% | 56.58% | 41.40% | 40.24% | 40.03% | 40.14% | 40.22% | 40.39% | 40.64% | 39.67% | 40.14% |
| Public | 42.26% | 42.12% | 41.86% | 41.83% | 41.57% | 42.42% | 43.42% | 58.60% | 59.76% | 59.97% | 59.86% | 59.78% | 59.61% | 59.36% | 60.33% | 59.86% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Lotus Eye Hospital and Institute Limited | ₹239.37 Cr | ₹114.68 | 1438.8 | 3.98 | 0.1% | 0.26 | +8.0% | -10.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 19
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Lotus Eye Hospital and Institute Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
marketscreener.com · 1 month ago